|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions |
ISO |
[Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 mRNA; [Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 protein; [Bucladesine co-treated with LIPE protein] results in increased expression of ABCA1 protein; Oligomycins inhibits the reaction [[Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 protein]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 mRNA] |
CTD |
PMID:20083572 PMID:23227865 PMID:23362264 |
|
NCBI chr 5:69,857,717...69,983,042
Ensembl chr 5:69,857,771...69,983,015
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions |
EXP |
Bucladesine inhibits the reaction [tert-Butylhydroperoxide affects the localization of ABCB11 protein] |
CTD |
PMID:16452108 |
|
NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions increases activity affects localization increases expression |
EXP ISO |
Bucladesine inhibits the reaction [estradiol-17 beta-glucuronide affects the localization of ABCC2 protein]; KT 5720 inhibits the reaction [Bucladesine affects the localization of ABCC2 protein] Bucladesine results in increased activity of ABCC2 protein Bucladesine results in increased expression of ABCC2 mRNA; Bucladesine results in increased expression of ABCC2 protein Bucladesine promotes the reaction [ATF2 protein binds to ABCC2 promoter]; Bucladesine promotes the reaction [JUN protein binds to ABCC2 promoter]; Bucladesine results in increased activity of and affects the localization of ABCC2 protein; Dactinomycin inhibits the reaction [Bucladesine results in increased expression of ABCC2 mRNA]; KT 5720 inhibits the reaction [Bucladesine affects the localization of ABCC2 protein]; KT 5720 inhibits the reaction [Bucladesine results in increased expression of ABCC2 mRNA]; KT 5720 inhibits the reaction [Bucladesine results in increased expression of ABCC2 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of ABCC2 protein]; verlukast inhibits the reaction [Bucladesine results in increased activity of ABCC2 protein] |
CTD |
PMID:12029626 PMID:26049102 PMID:29052767 |
|
NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
|
|
G |
Ache |
acetylcholinesterase |
increases activity increases expression |
EXP |
Bucladesine results in increased activity of ACHE protein; Bucladesine results in increased activity of ACHE protein alternative form Bucladesine results in increased expression of ACHE mRNA |
CTD |
PMID:18514641 |
|
NCBI chr12:22,472,358...22,477,052
Ensembl chr12:22,472,358...22,478,753
|
|
G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ADAMTS1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr11:25,342,119...25,350,938
Ensembl chr11:25,342,126...25,350,974
|
|
G |
Adm |
adrenomedullin |
decreases expression |
ISO |
Bucladesine results in decreased expression of ADM mRNA |
CTD |
PMID:19253104 |
|
NCBI chr 1:175,443,189...175,447,260
Ensembl chr 1:175,445,088...175,447,259
|
|
G |
Ahr |
aryl hydrocarbon receptor |
affects localization increases activity multiple interactions |
ISO |
Bucladesine affects the localization of AHR protein Bucladesine results in increased activity of AHR protein Bucladesine affects the reaction [Tetrachlorodibenzodioxin results in increased activity of AHR protein] |
CTD |
PMID:15972329 |
|
NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
|
|
G |
Ahrr |
aryl-hydrocarbon receptor repressor |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of AHRR mRNA] |
CTD |
PMID:21979172 |
|
NCBI chr 1:31,603,297...31,698,329
Ensembl chr 1:31,603,297...31,698,329
|
|
G |
Ak5 |
adenylate kinase 5 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of AK5 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:257,671,772...257,864,385
Ensembl chr 2:257,671,772...257,864,385
|
|
G |
Akap2 |
A-kinase anchoring protein 2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PALM2AKAP2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:74,874,245...74,985,789
Ensembl chr 5:74,874,306...74,982,401
|
|
G |
Alas1 |
5'-aminolevulinate synthase 1 |
multiple interactions |
ISO |
[NFE2L2 gene mutant form results in increased susceptibility to Bucladesine] which results in increased expression of ALAS1 mRNA |
CTD |
PMID:22859313 |
|
NCBI chr 8:114,927,704...114,941,038
Ensembl chr 8:114,927,722...114,940,177
|
|
G |
Antxr1 |
ANTXR cell adhesion molecule 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of ANTXR1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:118,946,267...119,131,202
Ensembl chr 4:118,946,268...119,131,202
|
|
G |
Anxa2 |
annexin A2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ANXA2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:75,687,134...75,723,589
Ensembl chr 8:75,687,100...75,723,594
|
|
G |
Apoa1 |
apolipoprotein A1 |
multiple interactions |
ISO |
27-hydroxycholesterol promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; 27-hydroxycholesterol promotes the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; [Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 mRNA; [Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 protein; [Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol; Oligomycins inhibits the reaction [[Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 protein]; Probucol inhibits the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; Probucol inhibits the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 mRNA]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; TO-901317 promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol] |
CTD |
PMID:20083572 PMID:23227865 |
|
NCBI chr 8:50,525,091...50,526,875
Ensembl chr 8:50,525,091...50,526,875
|
|
G |
Ar |
androgen receptor |
multiple interactions |
EXP |
[Quercetin co-treated with Bucladesine] results in increased expression of AR mRNA |
CTD |
PMID:23200735 |
|
NCBI chr X:67,656,253...67,828,998
Ensembl chr X:67,656,253...67,829,026
|
|
G |
Arhgef2 |
Rho/Rac guanine nucleotide exchange factor 2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ARHGEF2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:187,964,100...188,022,847
Ensembl chr 2:187,977,008...188,021,377
|
|
G |
Atf1 |
activating transcription factor 1 |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [Dinoprostone results in increased phosphorylation of ATF1 protein]] |
CTD |
PMID:12164941 |
|
NCBI chr 7:141,882,261...141,924,790
Ensembl chr 7:141,882,251...141,924,788
|
|
G |
Atf2 |
activating transcription factor 2 |
multiple interactions increases phosphorylation increases expression |
ISO |
Bucladesine promotes the reaction [ATF2 protein binds to ABCC2 promoter]; Bucladesine promotes the reaction [JUN protein binds to ATF2 protein]; KT 5720 inhibits the reaction [Bucladesine results in increased expression of ATF2 protein modified form] Bucladesine results in increased phosphorylation of ATF2 protein |
CTD |
PMID:26049102 |
|
NCBI chr 3:60,721,137...60,795,951
Ensembl chr 3:60,721,135...60,795,951
|
|
G |
Atp11a |
ATPase phospholipid transporting 11A |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of ATP11A mRNA |
CTD |
PMID:20823114 |
|
NCBI chr16:81,990,340...82,100,222
Ensembl chr16:81,990,340...82,100,222
|
|
G |
Atp2b1 |
ATPase plasma membrane Ca2+ transporting 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ATP2B1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 7:41,114,606...41,223,138
Ensembl chr 7:41,114,697...41,220,579
|
|
G |
Atp6v0c |
ATPase H+ transporting V0 subunit C |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of ATP6V0C mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:13,537,031...13,543,407
Ensembl chr10:13,537,033...13,542,077
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
adenosine-3',5'-cyclic phosphorothioate inhibits the reaction [Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]]; Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein] |
CTD |
PMID:16822680 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcat1 |
branched chain amino acid transaminase 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of BCAT1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:179,259,305...179,340,021
Ensembl chr 4:179,259,308...179,339,795
|
|
G |
Bckdk |
branched chain ketoacid dehydrogenase kinase |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of BCKDK mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:199,351,628...199,356,299
Ensembl chr 1:199,351,628...199,356,881
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
ISO |
adenosine-3',5'-cyclic phosphorothioate inhibits the reaction [Bucladesine inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]]; Bucladesine inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein] Bucladesine results in decreased expression of BCL2 protein |
CTD |
PMID:10697531 PMID:16822680 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bcl2l13 |
BCL2 like 13 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of BCL2L13 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:153,385,200...153,438,096
Ensembl chr 4:153,385,205...153,436,660
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions increases expression |
ISO |
1-bromopropane inhibits the reaction [Bucladesine results in increased expression of BDNF mRNA]; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of ENO2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of MAP2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFL mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFM mRNA |
CTD |
PMID:19189864 PMID:29698629 |
|
NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210
|
|
G |
Bet1l |
Bet1 golgi vesicular membrane trafficking protein-like |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of BET1L mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:213,602,836...213,606,507
Ensembl chr 1:213,602,850...213,605,643
|
|
G |
Bicd1 |
BICD cargo adaptor 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of BICD1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:184,018,845...184,167,628
Ensembl chr 4:184,019,087...184,165,540
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [BMP4 protein results in increased expression of SMAD6 mRNA] |
CTD |
PMID:20522807 |
|
NCBI chr15:20,776,060...20,791,013
Ensembl chr15:20,776,054...20,822,740
|
|
G |
Bsnd |
barttin CLCNK type accessory subunit beta |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of BSND mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:126,071,849...126,080,647
Ensembl chr 5:126,071,846...126,080,698
|
|
G |
C1r |
complement C1r |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of C1R mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:157,126,060...157,136,825
Ensembl chr 4:157,125,998...157,136,829
|
|
G |
Calm1 |
calmodulin 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CALM1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 6:124,217,241...124,225,292
Ensembl chr 6:124,217,241...124,225,292
|
|
G |
Calr |
calreticulin |
increases stability |
ISO |
Bucladesine results in increased stability of CALR protein |
CTD |
PMID:9473613 |
|
NCBI chr19:25,956,771...25,961,666
Ensembl chr19:25,956,771...25,961,666
|
|
G |
Capn2 |
calpain 2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CAPN2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr13:100,878,649...100,928,811
Ensembl chr13:100,878,650...100,928,811
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [CASP3 protein results in increased cleavage of RB1 protein]; Bucladesine promotes the reaction [Hydroxyurea results in increased activity of CASP3 protein] |
CTD |
PMID:10697531 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Cast |
calpastatin |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CAST mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:1,452,111...1,561,669
Ensembl chr 2:1,452,116...1,561,464
|
|
G |
Cav2 |
caveolin 2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CAV2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:44,573,264...44,580,640
Ensembl chr 4:44,573,264...44,580,638
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of CCL3 protein] |
CTD |
PMID:12538206 |
|
NCBI chr10:70,869,516...70,871,066
Ensembl chr10:70,869,513...70,871,066
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CCN2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:21,851,657...21,854,773
Ensembl chr 1:21,851,660...21,854,773
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions |
ISO |
[Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in increased expression of CCNB1 mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of CCNB1 protein |
CTD |
PMID:22534328 |
|
NCBI chr 2:30,782,133...30,791,106
Ensembl chr 2:30,783,915...30,791,221
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression multiple interactions |
EXP ISO |
Bucladesine results in increased expression of CCND1 protein [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] affects the expression of CCND1 protein; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in decreased expression of CCND1 mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in decreased expression of CCND1 mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in decreased expression of CCND1 protein |
CTD |
PMID:16718685 PMID:21693435 PMID:22534328 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Ccnd3 |
cyclin D3 |
increases expression |
EXP |
Bucladesine results in increased expression of CCND3 protein |
CTD |
PMID:16718685 |
|
NCBI chr 9:15,404,816...15,410,905
Ensembl chr 9:15,404,822...15,410,943
|
|
G |
Cd69 |
Cd69 molecule |
decreases expression |
ISO |
Bucladesine results in decreased expression of CD69 protein |
CTD |
PMID:25433234 |
|
NCBI chr 4:163,041,147...163,049,065
Ensembl chr 4:163,041,141...163,049,084
|
|
G |
Cd80 |
Cd80 molecule |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of CD80 protein] |
CTD |
PMID:12538815 |
|
NCBI chr11:64,815,201...64,855,293
Ensembl chr11:64,827,635...64,855,353
|
|
G |
Cdc42bpa |
CDC42 binding protein kinase alpha |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CDC42BPA mRNA |
CTD |
PMID:20823114 |
|
NCBI chr13:98,231,326...98,447,762
Ensembl chr13:98,231,326...98,447,762
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression multiple interactions |
EXP ISO |
Bucladesine results in increased expression of CDKN1A protein [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CDKN1A mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in increased expression of CDKN1A mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of CDKN1A protein GJA1 promotes the reaction [Bucladesine results in increased expression of CDKN1A protein] |
CTD |
PMID:16718685 PMID:20823114 PMID:22534328 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression |
EXP |
Bucladesine results in increased expression of CDKN1B protein |
CTD |
PMID:16718685 PMID:21693435 |
|
NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
increases expression multiple interactions |
ISO |
Bucladesine results in increased expression of CEBPB protein Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of CEBPB protein] |
CTD |
PMID:19282384 PMID:19698295 |
|
NCBI chr 3:164,424,502...164,425,933
Ensembl chr 3:164,424,515...164,425,910
|
|
G |
Cebpz |
CCAAT/enhancer binding protein zeta |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CEBPZ mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 6:1,516,804...1,534,488
Ensembl chr 6:1,516,804...1,534,488
|
|
G |
Chat |
choline O-acetyltransferase |
multiple interactions increases expression |
ISO EXP |
[Bucladesine co-treated with Tretinoin] results in increased activity of CHAT protein; [Tretinoin co-treated with Bucladesine] results in increased activity of CHAT protein Bucladesine results in increased expression of CHAT protein Nicotine promotes the reaction [Bucladesine results in increased expression of CHAT protein] |
CTD |
PMID:16724269 PMID:20361958 PMID:29665406 |
|
NCBI chr16:8,576,858...8,686,131
Ensembl chr16:8,577,840...8,686,131
|
|
G |
Cldn5 |
claudin 5 |
increases expression |
ISO |
Bucladesine results in increased expression of CLDN5 mRNA |
CTD |
PMID:20711499 |
|
NCBI chr11:86,356,292...86,357,718
Ensembl chr11:86,356,294...86,357,718
|
|
G |
Cngb1 |
cyclic nucleotide gated channel subunit beta 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CNGB1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr19:10,142,440...10,206,618
Ensembl chr19:10,142,496...10,206,681
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] |
CTD |
PMID:11576339 PMID:16430859 |
|
NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [TGFB1 protein results in increased expression of COL3A1 mRNA] |
CTD |
PMID:11576339 |
|
NCBI chr 9:52,023,295...52,059,221
Ensembl chr 9:52,023,295...52,059,217
|
|
G |
Col6a2 |
collagen type VI alpha 2 chain |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of COL6A2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr20:12,773,472...12,801,179
Ensembl chr20:12,773,427...12,801,180
|
|
G |
Col6a3 |
collagen type VI alpha 3 chain |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of COL6A3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 9:97,926,784...98,004,643
Ensembl chr 9:97,926,787...98,004,546
|
|
G |
Cox6a2 |
cytochrome c oxidase subunit 6A2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of COX6A2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:199,624,037...199,626,255
Ensembl chr 1:199,624,037...199,624,783
|
|
G |
Cplx1 |
complexin 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CPLX1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr14:2,194,895...2,226,610
Ensembl chr14:2,194,933...2,226,598
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
increases phosphorylation multiple interactions |
ISO |
Bucladesine results in increased phosphorylation of CREB1 protein Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [Dinoprostone results in increased phosphorylation of CREB1 protein]] [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]] promotes the reaction [CREBBP protein binds to STAR promoter]; bisindolylmaleimide I inhibits the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]; CREB1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; CREBBP protein promotes the reaction [CREB1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:12164941 PMID:18787026 PMID:19282384 |
|
NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
|
|
G |
Crebbp |
CREB binding protein |
multiple interactions |
ISO |
Bucladesine promotes the reaction [CREBBP protein binds to SOD2 promoter] [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]] promotes the reaction [CREBBP protein binds to STAR promoter]; CREBBP protein promotes the reaction [CREB1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]] |
CTD |
PMID:19282384 PMID:20685861 |
|
NCBI chr10:11,590,994...11,721,039
Ensembl chr10:11,595,044...11,721,039
|
|
G |
Crem |
cAMP responsive element modulator |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CREM mRNA |
CTD |
PMID:20823114 |
|
NCBI chr17:57,021,704...57,090,888
Ensembl chr17:57,031,766...57,090,888
|
|
G |
Cryab |
crystallin, alpha B |
multiple interactions |
EXP |
Bucladesine inhibits the reaction [arsenite results in increased expression of CRYAB protein] |
CTD |
PMID:8769853 |
|
NCBI chr 8:55,178,543...55,182,546
Ensembl chr 8:55,178,289...55,182,545
|
|
G |
Csf1r |
colony stimulating factor 1 receptor |
multiple interactions |
ISO |
Bucladesine promotes the reaction [Tretinoin results in increased expression of CSF1R mRNA] |
CTD |
PMID:8445950 |
|
NCBI chr18:56,414,493...56,458,300
Ensembl chr18:56,414,488...56,458,300
|
|
G |
Ctbp1 |
C-terminal binding protein 1 |
multiple interactions affects localization |
ISO |
Bucladesine inhibits the reaction [CTBP1 protein binds to KAT2A protein]; Bucladesine inhibits the reaction [CTBP1 protein binds to NR5A1 protein]; Bucladesine promotes the reaction [CTBP1 protein binds to CTBP2 protein] Bucladesine affects the localization of CTBP1 protein |
CTD |
PMID:18184656 |
|
NCBI chr14:82,762,109...82,789,350
Ensembl chr14:82,762,190...82,789,319
|
|
G |
Ctbp2 |
C-terminal binding protein 2 |
affects localization multiple interactions |
ISO |
Bucladesine affects the localization of CTBP2 protein Bucladesine promotes the reaction [CTBP1 protein binds to CTBP2 protein] |
CTD |
PMID:18184656 |
|
NCBI chr 1:205,001,354...205,030,565
Ensembl chr 1:205,001,396...205,040,755
|
|
G |
Ctnnb1 |
catenin beta 1 |
increases phosphorylation |
EXP |
Bucladesine results in increased phosphorylation of CTNNB1 protein |
CTD |
PMID:26964897 |
|
NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
|
|
G |
Ctps2 |
CTP synthase 2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CTPS2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr X:33,383,087...33,522,852
Ensembl chr X:33,383,087...33,522,836
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
decreases expression |
ISO |
Bucladesine results in decreased expression of CXCL12 mRNA |
CTD |
PMID:20711499 |
|
NCBI chr 4:149,261,044...149,273,891
Ensembl chr 4:149,261,044...149,273,891
|
|
G |
Cyb5d1 |
cytochrome b5 domain containing 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CYB5D1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:55,993,206...55,997,429
Ensembl chr10:55,995,823...55,997,299
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
increases expression multiple interactions |
EXP ISO |
Bucladesine results in increased expression of CYP11A1 mRNA [Atrazine co-treated with Bucladesine] results in increased expression of CYP11A1 mRNA; Atrazine inhibits the reaction [Bucladesine results in increased expression of CYP11A1 mRNA]; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of CYP11A1 mRNA] |
CTD |
PMID:21693180 PMID:21979172 PMID:23200735 |
|
NCBI chr 8:62,798,317...62,809,848
Ensembl chr 8:62,779,875...62,809,893
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
decreases expression increases expression multiple interactions |
EXP |
Bucladesine results in decreased expression of CYP17A1 mRNA Bucladesine results in increased expression of CYP17A1 mRNA [Atrazine co-treated with Bucladesine] results in increased expression of CYP17A1 mRNA; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of CYP17A1 mRNA] |
CTD |
PMID:21458522 PMID:21693180 PMID:23200735 |
|
NCBI chr 1:266,422,127...266,429,947
Ensembl chr 1:266,422,132...266,428,239
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
EXP ISO |
Bucladesine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; Bucladesine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Bucladesine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein] Bucladesine affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:1849469 PMID:16901605 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
Bucladesine affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A2 mRNA] |
CTD |
PMID:1849469 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression |
ISO |
Bucladesine results in increased expression of CYP1B1 mRNA |
CTD |
PMID:11559018 |
|
NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722
|
|
G |
Cyp2a3 |
cytochrome P450, family 2, subfamily a, polypeptide 3 |
increases expression multiple interactions |
ISO |
Bucladesine results in increased expression of CYP2A5 mRNA NFE2L2 gene mutant form promotes the reaction [Bucladesine results in increased expression of CYP2A5 mRNA] |
CTD |
PMID:11162586 PMID:22859313 |
|
NCBI chr 1:83,653,248...83,662,118
Ensembl chr 1:83,653,234...83,766,484
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
ISO |
Bucladesine promotes the reaction [CYP2E1 protein results in increased oxidation of 4-nitrophenol] |
CTD |
PMID:8531136 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Dcn |
decorin |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of DCN protein; Azacitidine promotes the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of DCN protein] |
CTD |
PMID:20823114 |
|
NCBI chr 7:38,742,250...38,782,282
Ensembl chr 7:38,742,051...38,782,323
|
|
G |
Ddx27 |
DEAD-box helicase 27 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of DDX27 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:163,767,236...163,786,408
Ensembl chr 3:163,767,173...163,786,445
|
|
G |
Des |
desmin |
multiple interactions |
EXP ISO |
[Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of DES mRNA [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of DES mRNA |
CTD |
PMID:19089455 PMID:20823114 |
|
NCBI chr 9:82,556,574...82,564,288
Ensembl chr 9:82,556,573...82,564,294
|
|
G |
Dhx9 |
DExH-box helicase 9 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of DHX9 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr13:70,885,503...70,922,278
Ensembl chr13:70,885,504...70,922,245
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of DIO2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 6:114,475,156...114,489,443
Ensembl chr 6:114,476,142...114,476,723
|
|
G |
Dtymk |
deoxythymidylate kinase |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of DTYMK mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 9:100,921,565...100,930,399
Ensembl chr 9:100,921,565...100,930,399
|
|
G |
Eda |
ectodysplasin-A |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of EDA mRNA |
CTD |
PMID:20823114 |
|
NCBI chr X:69,730,123...70,222,693
Ensembl chr X:69,730,242...70,220,329
|
|
G |
Eef1a1 |
eukaryotic translation elongation factor 1 alpha 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of EEF1A1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:85,838,594...85,841,816
Ensembl chr 8:85,838,869...85,840,818
|
|
G |
Efemp1 |
EGF containing fibulin extracellular matrix protein 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of EFEMP1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr14:113,202,382...113,294,993
Ensembl chr14:113,202,419...113,295,014
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
[Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of ENO2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of MAP2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFL mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFM mRNA |
CTD |
PMID:29698629 |
|
NCBI chr 2:68,820,616...68,895,537
|
|
G |
Egr2 |
early growth response 2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of EGR2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr20:22,452,170...22,461,018
Ensembl chr20:22,454,463...22,459,025
|
|
G |
Eno2 |
enolase 2 |
multiple interactions |
ISO |
[Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of ENO2 mRNA |
CTD |
PMID:29698629 |
|
NCBI chr 4:157,285,192...157,294,090
Ensembl chr 4:157,285,179...157,294,047 Ensembl chr 9:157,285,179...157,294,047
|
|
G |
Epb41l4a |
erythrocyte membrane protein band 4.1 like 4A |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of EPB41L4A mRNA |
CTD |
PMID:20823114 |
|
NCBI chr18:26,570,051...26,788,586
Ensembl chr18:26,570,647...26,658,892
|
|
G |
Epha3 |
Eph receptor A3 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of EPHA3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr11:421,253...783,037
Ensembl chr11:421,135...782,954
|
|
G |
Esr1 |
estrogen receptor 1 |
increases expression multiple interactions |
EXP |
Bucladesine results in increased expression of ESR1 mRNA [Quercetin co-treated with Bucladesine] results in increased expression of ESR1 mRNA; Atrazine inhibits the reaction [Bucladesine results in increased expression of ESR1 mRNA] |
CTD |
PMID:21693180 PMID:23200735 |
|
NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
|
|
G |
Eya1 |
EYA transcriptional coactivator and phosphatase 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of EYA1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:4,275,728...4,495,525
Ensembl chr 5:4,373,626...4,513,142
|
|
G |
Fads2 |
fatty acid desaturase 2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of FADS2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:225,906,582...226,152,568
Ensembl chr 1:226,114,413...226,152,524
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression multiple interactions |
EXP |
Bucladesine results in increased expression of FAS mRNA N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of FAS mRNA] |
CTD |
PMID:12414803 |
|
NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
|
|
G |
Fbxo11 |
F-box protein 11 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of FBXO11 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 6:11,662,356...11,737,427
Ensembl chr 6:11,662,356...11,686,682
|
|
G |
Fbxw5 |
F-box and WD repeat domain containing 5 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of FBXW5 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:2,726,705...2,731,213
Ensembl chr 3:2,727,254...2,731,212
|
|
G |
Fcer2 |
Fc fragment of IgE receptor II |
decreases expression |
ISO |
Bucladesine results in decreased expression of FCER2 protein |
CTD |
PMID:1328389 |
|
NCBI chr12:2,233,772...2,245,324
Ensembl chr12:2,233,778...2,245,324
|
|
G |
Fgd1 |
FYVE, RhoGEF and PH domain containing 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of FGD1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr X:20,100,942...20,143,871
Ensembl chr X:20,216,587...20,225,955 Ensembl chr X:20,216,587...20,225,955
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
ISO |
[Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of ENO2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of MAP2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFL mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFM mRNA |
CTD |
PMID:29698629 |
|
NCBI chr 2:124,081,072...124,134,133
Ensembl chr 2:124,081,072...124,134,681
|
|
G |
Fgf9 |
fibroblast growth factor 9 |
multiple interactions |
ISO |
FGF9 protein inhibits the reaction [Bucladesine promotes the reaction [IGF1 protein results in increased abundance of Estradiol]]; FGF9 protein inhibits the reaction [IGF1 protein promotes the reaction [Bucladesine results in increased abundance of Progesterone]]; FGF9 protein promotes the reaction [Bucladesine results in increased abundance of Progesterone] |
CTD |
PMID:22798350 |
|
NCBI chr15:38,341,657...38,386,945
Ensembl chr15:38,341,089...38,387,316
|
|
G |
Filip1l |
filamin A interacting protein 1-like |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of FILIP1L mRNA |
CTD |
PMID:20823114 |
|
NCBI chr11:45,039,488...45,275,141
Ensembl chr11:45,039,461...45,124,423
|
|
G |
Fkbp5 |
FKBP prolyl isomerase 5 |
multiple interactions |
ISO |
[bisphenol A co-treated with Bucladesine] results in increased methylation of FKBP5 intron; [Bucladesine co-treated with bisphenol A] results in decreased expression of FKBP5 mRNA; [Bucladesine co-treated with bisphenol A] results in decreased expression of FKBP5 protein; [Bucladesine co-treated with Dexamethasone] results in increased expression of FKBP5 mRNA; [Bucladesine co-treated with fulvestrant] results in decreased expression of FKBP5 mRNA; [Bucladesine co-treated with fulvestrant] results in decreased expression of FKBP5 protein; [fulvestrant co-treated with Bucladesine] results in increased methylation of FKBP5 intron; bisphenol A promotes the reaction [[fulvestrant co-treated with Bucladesine] results in increased methylation of FKBP5 intron]; Dexamethasone inhibits the reaction [[Bucladesine co-treated with bisphenol A] results in decreased expression of FKBP5 mRNA]; Estradiol inhibits the reaction [[Bucladesine co-treated with fulvestrant] results in decreased expression of FKBP5 mRNA] |
CTD |
PMID:26427651 |
|
NCBI chr20:7,976,704...8,097,290
Ensembl chr20:7,976,713...8,019,020
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of FN1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 9:78,900,111...78,969,018
Ensembl chr 9:78,900,103...78,969,078
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
affects expression multiple interactions increases expression |
ISO |
Bucladesine affects the expression of FOS protein Bucladesine results in increased expression of and results in increased phosphorylation of FOS protein; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of FOS protein] Bucladesine results in increased expression of FOS mRNA; Bucladesine results in increased expression of FOS protein |
CTD |
PMID:7798212 PMID:9187264 PMID:19282384 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of FOXO1 mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of FOXO1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:141,451,234...141,527,016
Ensembl chr 2:141,451,234...141,527,016
|
|
G |
Fscn2 |
fascin actin-bundling protein 2, retinal |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of FSCN2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:109,528,307...109,540,675
Ensembl chr10:109,533,487...109,540,026
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
increases expression multiple interactions |
ISO |
Bucladesine results in increased expression of G6PC mRNA; Bucladesine results in increased expression of G6PC protein IL22 protein inhibits the reaction [Bucladesine results in increased expression of G6PC protein]; NFE2L2 gene mutant form promotes the reaction [Bucladesine results in increased expression of G6PC mRNA]; STAT3 gene mutant form affects the reaction [IL22 protein inhibits the reaction [Bucladesine results in increased expression of G6PC protein]] |
CTD |
PMID:22859313 PMID:26064446 |
|
NCBI chr10:89,286,009...89,296,213
Ensembl chr10:89,285,855...89,296,213
|
|
G |
Gars |
glycyl-tRNA synthetase |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of GARS1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:85,235,122...85,276,085
Ensembl chr 4:85,235,172...85,276,044
|
|
G |
Gbe1 |
1,4-alpha-glucan branching enzyme 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of GBE1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr11:7,210,169...7,485,895
Ensembl chr11:7,210,209...7,485,890
|
|
G |
Gbp2 |
guanylate binding protein 2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of GBP2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:248,276,795...248,293,784
Ensembl chr 2:248,276,709...248,293,784
|
|
G |
Gcnt2 |
glucosaminyl (N-acetyl) transferase 2 (I blood group) |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of GCNT2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr17:21,634,546...21,677,477
Ensembl chr17:21,634,551...21,739,408
|
|
G |
Gdf3 |
growth differentiation factor 3 |
affects expression multiple interactions |
ISO |
Bucladesine affects the expression of GDF3 mRNA; Bucladesine affects the expression of GDF3 protein bisphenol A affects the reaction [Bucladesine affects the expression of GDF3 mRNA]; bisphenol A affects the reaction [Bucladesine affects the expression of GDF3 protein]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of GDF3 mRNA]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of GDF3 protein]; Paraquat affects the reaction [Bucladesine affects the expression of GDF3 mRNA]; Paraquat affects the reaction [Bucladesine affects the expression of GDF3 protein] |
CTD |
PMID:31400064 |
|
NCBI chr 4:155,417,667...155,422,014
Ensembl chr 4:155,417,004...155,421,998
|
|
G |
Gipc1 |
GIPC PDZ domain containing family, member 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of GIPC1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr19:24,786,604...24,798,231
Ensembl chr19:24,786,628...24,798,233
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
multiple interactions increases expression |
EXP |
GJA1 promotes the reaction [Bucladesine results in increased expression of CDKN1A protein]; Tolbutamide promotes the reaction [Bucladesine results in increased expression of GJA1 protein] |
CTD |
PMID:11741589 PMID:16718685 |
|
NCBI chr20:37,876,650...37,889,097
Ensembl chr20:37,876,650...37,889,089
|
|
G |
Gpd1 |
glycerol-3-phosphate dehydrogenase 1 |
multiple interactions |
ISO |
Bucladesine promotes the reaction [Bezafibrate results in increased expression of GPD1 mRNA] |
CTD |
PMID:1976021 |
|
NCBI chr 7:141,368,928...141,377,931
Ensembl chr 7:141,370,491...141,377,928
|
|
G |
Gpkow |
G patch domain and KOW motifs |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of GPKOW mRNA |
CTD |
PMID:20823114 |
|
NCBI chr X:15,636,567...15,651,332
Ensembl chr X:15,636,563...15,651,332
|
|
G |
Gpnmb |
glycoprotein nmb |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of GPNMB mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:78,694,447...78,715,685
Ensembl chr 4:78,694,447...78,715,683
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
multiple interactions increases expression |
ISO |
KT 5720 inhibits the reaction [Bucladesine results in increased expression of GSTA1 mRNA] |
CTD |
PMID:26049102 |
|
NCBI chr 9:27,366,404...27,381,004
Ensembl chr 9:27,368,272...27,452,902
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
increases expression multiple interactions |
ISO |
Bucladesine results in increased expression of GSTA2 mRNA KT 5720 inhibits the reaction [Bucladesine results in increased expression of GSTA2 mRNA] |
CTD |
PMID:26049102 |
|
NCBI chr 8:85,640,081...85,645,621
|
|
G |
Gsta4 |
glutathione S-transferase alpha 4 |
increases expression multiple interactions |
ISO |
Bucladesine results in increased expression of GSTA4 mRNA KT 5720 inhibits the reaction [Bucladesine results in increased expression of GSTA4 mRNA] |
CTD |
PMID:26049102 |
|
NCBI chr 8:85,497,557...85,514,732
Ensembl chr 8:85,497,557...85,518,879
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
increases expression |
ISO |
Bucladesine results in increased expression of HIF1A mRNA |
CTD |
PMID:18591213 |
|
NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
|
|
G |
Hoxa1 |
homeobox A1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of HOXA1 mRNA; Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of HOXA1 mRNA] |
CTD |
PMID:20823114 |
|
NCBI chr 4:82,124,358...82,127,182
Ensembl chr 4:82,125,406...82,127,066
|
|
G |
Hsd17b12 |
hydroxysteroid (17-beta) dehydrogenase 12 |
increases expression |
EXP |
Bucladesine results in increased expression of HSD17B12 mRNA |
CTD |
PMID:21458522 |
|
NCBI chr 3:82,924,699...83,048,465
Ensembl chr 3:82,924,687...83,048,435
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
increases expression |
EXP |
Bucladesine results in increased expression of HSD3B1 mRNA |
CTD |
PMID:21458522 |
|
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
increases expression increases phosphorylation |
EXP ISO |
Bucladesine results in increased expression of HSP27 protein Bucladesine results in increased phosphorylation of HSPB1 protein |
CTD |
PMID:7541446 PMID:10559386 |
|
NCBI chr12:23,839,390...23,841,051
Ensembl chr12:23,839,399...23,841,049
|
|
G |
Htr1a |
5-hydroxytryptamine receptor 1A |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of HTR1A mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:36,246,628...36,247,896
Ensembl chr 2:36,246,628...36,247,896
|
|
G |
Iapp |
islet amyloid polypeptide |
increases expression |
EXP |
Bucladesine results in increased expression of IAPP mRNA |
CTD |
PMID:9142872 |
|
NCBI chr 4:176,509,863...176,517,903
Ensembl chr 4:176,510,696...176,516,083
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein] |
CTD |
PMID:12538815 |
|
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
|
|
G |
Id1 |
inhibitor of DNA binding 1, HLH protein |
increases expression multiple interactions |
ISO |
Bucladesine results in increased expression of ID1 protein N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of ID1 mRNA] |
CTD |
PMID:20522807 |
|
NCBI chr 3:148,214,623...148,216,715
Ensembl chr 3:148,215,540...148,216,718
|
|
G |
Ifrd2 |
interferon-related developmental regulator 2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IFRD2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:116,343,096...116,348,318
Ensembl chr 8:116,343,096...116,348,314
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions |
ISO |
Bucladesine promotes the reaction [IGF1 protein results in increased abundance of Estradiol]; FGF9 protein inhibits the reaction [Bucladesine promotes the reaction [IGF1 protein results in increased abundance of Estradiol]]; FGF9 protein inhibits the reaction [IGF1 protein promotes the reaction [Bucladesine results in increased abundance of Progesterone]]; IGF1 protein promotes the reaction [Bucladesine results in increased abundance of Progesterone] |
CTD |
PMID:22798350 |
|
NCBI chr 7:28,412,123...28,491,815
Ensembl chr 7:28,412,198...28,486,609
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
increases expression multiple interactions |
ISO |
Bucladesine results in increased expression of IGFBP1 [Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 protein; Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA]; Azacitidine promotes the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 protein] |
CTD |
PMID:12093828 PMID:20823114 PMID:30328349 |
|
NCBI chr14:87,448,716...87,453,783
Ensembl chr14:87,448,692...87,453,785
|
|
G |
Igfbp3 |
insulin-like growth factor binding protein 3 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr14:87,457,647...87,465,374
Ensembl chr14:87,457,647...87,465,374
|
|
G |
Igfbp4 |
insulin-like growth factor binding protein 4 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP4 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:86,950,555...86,962,563
Ensembl chr10:86,950,557...86,962,578
|
|
G |
Ighe |
immunoglobulin heavy constant epsilon |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [IL4 protein results in increased expression of IGHE mRNA alternative form]]; Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [IL4 protein results in increased expression of IGHE mRNA]] |
CTD |
PMID:12230500 |
|
NCBI chr 6:138,066,728...138,068,606
|
|
G |
Il10 |
interleukin 10 |
decreases expression multiple interactions |
ISO |
Bucladesine results in decreased expression of IL10 Bucladesine promotes the reaction [Zymosan results in increased expression of IL10 protein] |
CTD |
PMID:11301049 PMID:19273625 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IL12B mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085
|
|
G |
Il13 |
interleukin 13 |
decreases expression decreases secretion |
ISO |
Bucladesine results in decreased expression of IL13 mRNA Bucladesine results in decreased secretion of IL13 protein |
CTD |
PMID:16083514 |
|
NCBI chr10:38,982,909...38,985,466
Ensembl chr10:38,982,909...38,985,466
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
Bucladesine promotes the reaction [IL1B protein results in increased abundance of Nitrites]; Dipyridamole promotes the reaction [Bucladesine promotes the reaction [IL1B protein results in increased abundance of Nitrites]] |
CTD |
PMID:8904084 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il23a |
interleukin 23 subunit alpha |
increases expression multiple interactions |
ISO |
Bucladesine results in increased expression of IL23A mRNA [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of IL23A mRNA |
CTD |
PMID:19273625 PMID:20823114 |
|
NCBI chr 7:2,710,609...2,712,723
Ensembl chr 7:2,710,609...2,712,723
|
|
G |
Il2ra |
interleukin 2 receptor subunit alpha |
decreases expression |
ISO |
Bucladesine results in decreased expression of IL2RA protein |
CTD |
PMID:1709825 PMID:25433234 |
|
NCBI chr17:70,500,672...70,547,929
Ensembl chr17:70,499,083...70,548,071
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [Itraconazole results in decreased expression of IL4 mRNA]; Bucladesine inhibits the reaction [Itraconazole results in decreased secretion of IL4 protein]; Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [IL4 protein results in increased expression of IGHE mRNA alternative form]]; Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [IL4 protein results in increased expression of IGHE mRNA]]; Bucladesine inhibits the reaction [Ketoconazole results in decreased expression of IL4 mRNA]; Bucladesine inhibits the reaction [Ketoconazole results in decreased secretion of IL4 protein]; Bucladesine inhibits the reaction [Miconazole results in decreased expression of IL4 mRNA]; Bucladesine inhibits the reaction [Miconazole results in decreased secretion of IL4 protein]; Bucladesine inhibits the reaction [terbinafine results in decreased expression of IL4 mRNA]; Bucladesine inhibits the reaction [terbinafine results in decreased secretion of IL4 protein]; Bucladesine inhibits the reaction [Tolnaftate results in decreased expression of IL4 mRNA]; Bucladesine inhibits the reaction [Tolnaftate results in decreased secretion of IL4 protein] |
CTD |
PMID:11886533 PMID:12230500 |
|
NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
|
|
G |
Il5 |
interleukin 5 |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [Itraconazole results in decreased expression of IL5 mRNA]; Bucladesine inhibits the reaction [Itraconazole results in decreased secretion of IL5 protein]; Bucladesine inhibits the reaction [Ketoconazole results in decreased expression of IL5 mRNA]; Bucladesine inhibits the reaction [Ketoconazole results in decreased secretion of IL5 protein]; Bucladesine inhibits the reaction [Miconazole results in decreased expression of IL5 mRNA]; Bucladesine inhibits the reaction [Miconazole results in decreased secretion of IL5 protein]; Bucladesine inhibits the reaction [terbinafine results in decreased expression of IL5 mRNA]; Bucladesine inhibits the reaction [terbinafine results in decreased secretion of IL5 protein]; Bucladesine inhibits the reaction [Tolnaftate results in decreased expression of IL5 mRNA]; Bucladesine inhibits the reaction [Tolnaftate results in decreased secretion of IL5 protein] |
CTD |
PMID:11886533 |
|
NCBI chr10:39,066,716...39,069,587
Ensembl chr10:39,066,716...39,069,587
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
[Bucladesine co-treated with Theophylline] inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Bucladesine promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Bucladesine promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] |
CTD |
PMID:20388727 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Inha |
inhibin subunit alpha |
decreases expression multiple interactions |
EXP |
Bucladesine results in decreased expression of INHA mRNA [Atrazine co-treated with Bucladesine] results in increased expression of INHA mRNA; Atrazine inhibits the reaction [Bucladesine results in decreased expression of INHA mRNA]; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of INHA mRNA] |
CTD |
PMID:21693180 PMID:23200735 |
|
NCBI chr 9:82,700,482...82,703,383
Ensembl chr 9:82,700,468...82,703,400
|
|
G |
Insl3 |
insulin-like 3 |
multiple interactions increases expression |
EXP |
[Atrazine co-treated with Bucladesine] results in increased expression of INSL3 mRNA; Atrazine inhibits the reaction [Bucladesine results in increased expression of INSL3 mRNA]; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of INSL3 mRNA] |
CTD |
PMID:21458522 PMID:21693180 PMID:23200735 |
|
NCBI chr16:20,120,753...20,122,702
Ensembl chr16:20,121,352...20,122,696
|
|
G |
Ints7 |
integrator complex subunit 7 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of INTS7 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr13:110,257,571...110,310,413
Ensembl chr13:110,257,571...110,310,413
|
|
G |
Irf9 |
interferon regulatory factor 9 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IRF9 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr15:34,282,936...34,288,981
Ensembl chr15:34,282,936...34,288,138
|
|
G |
Isg20l2 |
interferon stimulated exonuclease gene 20-like 2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ISG20L2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:187,302,192...187,311,677
Ensembl chr 2:187,302,192...187,311,676
|
|
G |
Itgb1 |
integrin subunit beta 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ITGB1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr19:61,677,512...61,725,537
Ensembl chr19:61,677,542...61,725,535
|
|
G |
Itih5 |
inter-alpha-trypsin inhibitor heavy chain 5 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ITIH5 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr17:72,035,799...72,055,809 NCBI chr17:72,108,870...72,137,419
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression multiple interactions |
ISO |
Bucladesine results in increased expression of JUN mRNA; Bucladesine results in increased expression of JUN protein Bucladesine results in increased expression of JUN protein; Bucladesine results in increased expression of JUN protein modified form Bucladesine promotes the reaction [JUN protein binds to ABCC2 promoter]; Bucladesine promotes the reaction [JUN protein binds to ATF2 protein]; KT 5720 inhibits the reaction [Bucladesine results in increased expression of JUN protein modified form]; KT 5720 inhibits the reaction [Bucladesine results in increased expression of JUN protein] [Bucladesine co-treated with ciglitazone] results in increased expression of and results in increased phosphorylation of JUN protein; [ciglitazone co-treated with Bucladesine] promotes the reaction [JUN protein results in increased expression of STAR mRNA]; Bucladesine promotes the reaction [ciglitazone results in increased expression of JUN mRNA]; Bucladesine results in increased expression of and results in increased phosphorylation of JUN protein; ciglitazone promotes the reaction [Bucladesine results in increased expression of JUN mRNA]; GFX 109203x inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of JUN protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of JUN protein]]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of JUN protein]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of JUN protein] |
CTD |
PMID:9187264 PMID:18755854 PMID:19282384 PMID:19698295 PMID:26049102 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Kat2a |
lysine acetyltransferase 2A |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [CTBP1 protein binds to KAT2A protein] |
CTD |
PMID:18184656 |
|
NCBI chr10:88,611,586...88,619,558
Ensembl chr10:88,611,586...88,619,537
|
|
G |
Kcnc4 |
potassium voltage-gated channel subfamily C member 4 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of KCNC4 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:210,220,908...210,241,447
Ensembl chr 2:210,220,908...210,241,455
|
|
G |
Kng2 |
kininogen 2 |
increases activity |
EXP |
Bucladesine results in increased activity of KNG1 |
CTD |
PMID:1334751 |
|
NCBI chr11:81,509,185...81,516,759
|
|
G |
Krt8 |
keratin 8 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of KRT8 mRNA; Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of KRT8 mRNA] |
CTD |
PMID:20823114 |
|
NCBI chr 7:143,596,511...143,603,745
Ensembl chr 7:143,596,511...143,603,803
|
|
G |
Lamb2 |
laminin subunit beta 2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of LAMB2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:117,268,335...117,280,517
Ensembl chr 8:117,268,337...117,280,517
|
|
G |
Ldha |
lactate dehydrogenase A |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of LDHA mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:102,900,288...102,909,713
Ensembl chr 1:102,900,286...102,909,707
|
|
G |
Lep |
leptin |
decreases expression |
ISO |
Bucladesine results in decreased expression of LEP mRNA |
CTD |
PMID:9002984 |
|
NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
|
|
G |
Lgals3 |
galectin 3 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of LGALS3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr15:24,153,602...24,165,537
Ensembl chr15:24,141,651...24,165,537
|
|
G |
Lhcgr |
luteinizing hormone/choriogonadotropin receptor |
decreases expression multiple interactions |
EXP |
Bucladesine results in decreased expression of LHCGR mRNA [Atrazine co-treated with Bucladesine] results in increased expression of LHCGR mRNA; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of LHCGR mRNA] |
CTD |
PMID:21693180 PMID:23200735 |
|
NCBI chr 6:12,493,182...12,554,482
Ensembl chr 6:12,493,943...12,554,439
|
|
G |
Lipe |
lipase E, hormone sensitive type |
affects localization increases activity increases expression multiple interactions |
EXP ISO |
Bucladesine affects the localization of LIPE protein Bucladesine results in increased activity of LIPE protein Bucladesine results in increased expression of LIPE mRNA [Bucladesine co-treated with LIPE protein] results in increased expression of ABCA1 protein; [Bucladesine co-treated with LIPE protein] results in increased expression of and results in increased phosphorylation of STAR protein; Bucladesine results in increased expression of and results in increased phosphorylation of LIPE protein; CAY 10499 inhibits the reaction [Bucladesine results in increased activity of and results in increased phosphorylation of LIPE protein]; LIPE protein affects the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]; LIPE protein affects the reaction [Bucladesine results in increased expression of PLIN1 mRNA]; LIPE protein affects the reaction [Bucladesine results in increased expression of SCARB1 mRNA]; LIPE protein affects the reaction [Bucladesine results in increased expression of STAR mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide affects the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of LIPE protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of LIPE mRNA]; NR1H2 protein affects the reaction [Bucladesine results in increased phosphorylation of LIPE protein]; NR1H2 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased phosphorylation of LIPE protein]]; NR1H3 protein affects the reaction [Bucladesine results in increased phosphorylation of LIPE protein]; NR1H3 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased phosphorylation of LIPE protein]] |
CTD |
PMID:11160373 PMID:23362264 |
|
NCBI chr 1:82,248,031...82,266,727
Ensembl chr 1:82,248,046...82,266,727
|
|
G |
Lpar3 |
lysophosphatidic acid receptor 3 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of LPAR3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:252,090,634...252,159,221
Ensembl chr 2:252,090,669...252,159,903
|
|
G |
Ltbp1 |
latent transforming growth factor beta binding protein 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of LTBP1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 6:21,203,502...21,600,441
Ensembl chr 6:21,203,502...21,600,451
|
|
G |
Ltc4s |
leukotriene C4 synthase |
decreases secretion |
ISO |
Bucladesine results in decreased secretion of LTC4S protein |
CTD |
PMID:16083514 |
|
NCBI chr10:35,736,486...35,743,088
Ensembl chr10:35,737,664...35,739,625
|
|
G |
Map1a |
microtubule-associated protein 1A |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MAP1A mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:113,251,918...113,272,193
Ensembl chr 3:113,251,778...113,272,186
|
|
G |
Map2 |
microtubule-associated protein 2 |
multiple interactions |
ISO |
[Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of MAP2 mRNA |
CTD |
PMID:29698629 |
|
NCBI chr 9:73,204,753...73,462,965
Ensembl chr 9:73,319,710...73,462,972
|
|
G |
Map4k4 |
mitogen-activated protein kinase kinase kinase kinase 4 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of MAP4K4 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 9:46,657,444...46,782,545
Ensembl chr 9:46,657,575...46,782,545
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO |
3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol promotes the reaction [[1-Methyl-3-isobutylxanthine co-treated with Bucladesine] results in increased activity of MAPK1 protein]; [1-Methyl-3-isobutylxanthine co-treated with Bucladesine] results in increased activity of MAPK1 protein Bucladesine results in increased phosphorylation of MAPK1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Bucladesine results in increased phosphorylation of MAPK1 protein]; Bucladesine results in increased phosphorylation of and results in increased activity of MAPK1 protein; U 0126 inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased phosphorylation of and results in increased activity of MAPK1 protein]] |
CTD |
PMID:8526880 PMID:19282384 PMID:22875961 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol promotes the reaction [[1-Methyl-3-isobutylxanthine co-treated with Bucladesine] results in increased activity of MAPK3 protein]; [1-Methyl-3-isobutylxanthine co-treated with Bucladesine] results in increased activity of MAPK3 protein Bucladesine results in increased phosphorylation of MAPK3 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Bucladesine results in increased phosphorylation of MAPK3 protein]; Bucladesine results in increased phosphorylation of and results in increased activity of MAPK3 protein; U 0126 inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased phosphorylation of and results in increased activity of MAPK3 protein]] |
CTD |
PMID:8526880 PMID:19282384 PMID:22875961 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mgat4b |
alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase B |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of MGAT4B mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:35,726,501...35,736,338
Ensembl chr10:35,726,544...35,736,338
|
|
G |
Mir125a |
microRNA 125a |
decreases expression |
EXP ISO |
Bucladesine results in decreased expression of MIR125A mRNA |
CTD |
PMID:23045399 |
|
NCBI chr 1:59,704,827...59,704,911
Ensembl chr 1:59,704,827...59,704,911
|
|
G |
Mir145 |
microRNA 145 |
decreases expression |
EXP ISO |
Bucladesine results in decreased expression of MIR145 mRNA |
CTD |
PMID:23045399 |
|
NCBI chr18:56,969,907...56,969,994
Ensembl chr18:56,969,907...56,969,994
|
|
G |
Mir27b |
microRNA 27b |
multiple interactions |
ISO |
[Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MIR27B mRNA |
CTD |
PMID:30328349 |
|
NCBI chr17:823,461...823,557
Ensembl chr17:823,461...823,557
|
|
G |
Mir455 |
microRNA 455 |
decreases expression |
EXP ISO |
Bucladesine results in decreased expression of MIR455 mRNA |
CTD |
PMID:23045399 |
|
NCBI chr 5:79,097,208...79,097,285
Ensembl chr 5:79,097,208...79,097,285
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
decreases expression |
EXP |
Bucladesine results in decreased expression of MKI67 protein |
CTD |
PMID:16718685 |
|
NCBI chr 1:207,993,895...208,020,454
Ensembl chr 1:207,993,895...208,020,454
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of MMP2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
|
|
G |
Mthfd2 |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MTHFD2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:115,004,433...115,015,965
Ensembl chr 4:115,004,448...115,015,965
|
|
G |
Mtr |
5-methyltetrahydrofolate-homocysteine methyltransferase |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MTR mRNA |
CTD |
PMID:20823114 |
|
NCBI chr17:66,210,444...66,295,014
Ensembl chr17:66,210,461...66,295,014
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
decreases expression |
ISO |
Bucladesine results in decreased expression of MYC mRNA; Bucladesine results in decreased expression of MYC protein |
CTD |
PMID:7798212 PMID:9187264 |
|
NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
|
|
G |
Myh9 |
myosin, heavy chain 9 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYH9 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 7:118,740,005...118,792,507
Ensembl chr 7:118,741,110...118,792,625
|
|
G |
Myl12a |
myosin light chain 12A |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYL12A mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 9:119,325,282...119,333,012
Ensembl chr 9:119,325,283...119,332,967
|
|
G |
Myl12b |
myosin light chain 12B |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYL12B mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 9:119,307,168...119,321,500
Ensembl chr 9:119,307,176...119,321,500
|
|
G |
Mylk |
myosin light chain kinase |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYLK mRNA |
CTD |
PMID:20823114 |
|
NCBI chr11:69,013,060...69,260,039
Ensembl chr11:69,013,050...69,223,158
|
|
G |
Myof |
myoferlin |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYOF mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:256,585,410...256,734,727
Ensembl chr 1:256,585,410...256,734,730
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NCF1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr12:25,497,104...25,506,300
Ensembl chr12:25,497,104...25,506,300
|
|
G |
Ndst1 |
N-deacetylase and N-sulfotransferase 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of NDST1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr18:55,951,497...56,014,107
Ensembl chr18:55,955,389...55,992,885
|
|
G |
Nefl |
neurofilament light chain |
multiple interactions |
ISO |
[Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFL mRNA |
CTD |
PMID:29698629 |
|
NCBI chr15:44,799,378...44,803,251
Ensembl chr15:44,799,334...44,804,574
|
|
G |
Nefm |
neurofilament medium chain |
multiple interactions |
ISO |
[Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFM mRNA |
CTD |
PMID:29698629 |
|
NCBI chr15:44,855,307...44,860,604
Ensembl chr15:44,855,310...44,860,604
|
|
G |
Neurog1 |
neurogenin 1 |
multiple interactions affects expression |
ISO |
bisphenol A affects the reaction [Bucladesine affects the expression of NEUROG1 mRNA]; bisphenol A affects the reaction [Bucladesine affects the expression of NEUROG1 protein]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of NEUROG1 mRNA]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of NEUROG1 protein]; Paraquat affects the reaction [Bucladesine affects the expression of NEUROG1 mRNA]; Paraquat affects the reaction [Bucladesine affects the expression of NEUROG1 protein] Bucladesine affects the expression of NEUROG1 mRNA; Bucladesine affects the expression of NEUROG1 protein |
CTD |
PMID:31400064 |
|
NCBI chr17:9,154,656...9,156,175
Ensembl chr17:9,154,656...9,156,175
|
|
G |
Nexn |
nexilin (F actin binding protein) |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NEXN mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:257,452,937...257,484,607
Ensembl chr 2:257,453,347...257,484,587
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
multiple interactions increases response to substance |
ISO |
[NFE2L2 gene mutant form results in increased susceptibility to Bucladesine] which results in increased expression of ALAS1 mRNA; NFE2L2 gene mutant form promotes the reaction [Bucladesine results in increased expression of CYP2A5 mRNA]; NFE2L2 gene mutant form promotes the reaction [Bucladesine results in increased expression of G6PC mRNA] |
CTD |
PMID:22859313 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Ngf |
nerve growth factor |
multiple interactions |
ISO |
[Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of ENO2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of MAP2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFL mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFM mRNA |
CTD |
PMID:29698629 |
|
NCBI chr 2:204,886,158...204,939,523
Ensembl chr 2:204,886,202...204,940,453
|
|
G |
Nom1 |
nucleolar protein with MIF4G domain 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NOM1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:2,340,034...2,356,427
Ensembl chr 4:2,340,148...2,356,068
|
|
G |
Nphp1 |
nephrocystin 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of NPHP1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:120,316,048...120,370,089
Ensembl chr 3:120,316,047...120,373,500
|
|
G |
Nptxr |
neuronal pentraxin receptor |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NPTXR mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 7:121,011,678...121,029,754
Ensembl chr 7:121,011,680...121,029,754
|
|
G |
Npy |
neuropeptide Y |
increases expression |
EXP |
Bucladesine results in increased expression of NPY mRNA |
CTD |
PMID:19912776 |
|
NCBI chr 4:79,557,856...79,565,059
Ensembl chr 4:79,557,854...79,565,097 Ensembl chr 4:79,557,854...79,565,097
|
|
G |
Nr0b1 |
nuclear receptor subfamily 0, group B, member 1 |
decreases expression multiple interactions |
ISO |
Bucladesine results in decreased expression of NR0B1 mRNA; Bucladesine results in decreased expression of NR0B1 protein Cycloheximide inhibits the reaction [Bucladesine results in decreased expression of NR0B1 mRNA]; Dactinomycin inhibits the reaction [Bucladesine results in decreased expression of NR0B1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in decreased expression of NR0B1 protein]; NR0B1 protein inhibits the reaction [[Bucladesine results in increased expression of STAR protein] which results in increased abundance of Progesterone]; NR0B1 protein inhibits the reaction [Bucladesine results in increased expression of NR4A1 protein]; NR0B1 protein inhibits the reaction [NR4A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR0B1 protein inhibits the reaction [NR5A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]] |
CTD |
PMID:18787026 PMID:19282384 |
|
NCBI chr X:54,734,385...54,738,513
Ensembl chr X:54,734,385...54,738,513
|
|
G |
Nr1h2 |
nuclear receptor subfamily 1, group H, member 2 |
multiple interactions |
ISO |
NR1H2 protein affects the reaction [Bucladesine results in increased phosphorylation of LIPE protein]; NR1H2 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; NR1H2 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased phosphorylation of LIPE protein]] |
CTD |
PMID:23362264 |
|
NCBI chr 1:100,554,577...100,559,896
Ensembl chr 1:100,554,544...100,559,942
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
multiple interactions |
ISO |
NR1H3 protein affects the reaction [Bucladesine results in increased phosphorylation of LIPE protein]; NR1H3 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; NR1H3 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased phosphorylation of LIPE protein]] |
CTD |
PMID:23362264 |
|
NCBI chr 3:80,004,130...80,014,197
Ensembl chr 3:80,004,130...80,012,750
|
|
G |
Nr2f1 |
nuclear receptor subfamily 2, group F, member 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NR2F1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:5,569,954...5,579,894
Ensembl chr 2:5,569,935...5,579,894
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
multiple interactions increases expression |
ISO |
NR0B1 protein inhibits the reaction [Bucladesine results in increased expression of NR4A1 protein]; NR0B1 protein inhibits the reaction [NR4A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR4A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]; NR4A1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of NR4A1 protein] |
CTD |
PMID:18787026 PMID:19282384 |
|
NCBI chr 7:142,899,358...142,920,216
Ensembl chr 7:142,905,758...142,920,216
|
|
G |
Nr5a1 |
nuclear receptor subfamily 5, group A, member 1 |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [CTBP1 protein binds to NR5A1 protein] NR0B1 protein inhibits the reaction [NR5A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR5A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA] |
CTD |
PMID:18184656 PMID:18787026 |
|
NCBI chr 3:22,998,900...23,020,441
Ensembl chr 3:22,999,616...23,020,441
|
|
G |
Nrip1 |
nuclear receptor interacting protein 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NRIP1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr11:14,658,225...14,742,478
Ensembl chr11:14,658,225...14,741,563
|
|
G |
Nt5e |
5' nucleotidase, ecto |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of NT5E mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:95,969,002...96,012,733
Ensembl chr 8:95,968,652...96,012,696
|
|
G |
Ntf3 |
neurotrophin 3 |
increases expression |
EXP |
Bucladesine results in increased expression of NTF3 protein |
CTD |
PMID:19854260 |
|
NCBI chr 4:158,636,883...158,705,886
Ensembl chr 4:158,636,884...158,705,886
|
|
G |
Nts |
neurotensin |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NTS mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 7:44,111,594...44,120,998
Ensembl chr 7:44,111,151...44,121,130
|
|
G |
Nup155 |
nucleoporin 155 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NUP155 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:57,206,665...57,258,242
Ensembl chr 2:57,206,613...57,258,295
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
multiple interactions decreases activity |
ISO |
4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone promotes the reaction [Bucladesine results in decreased activity of ODC1 protein] |
CTD |
PMID:6284819 |
|
NCBI chr 6:42,852,529...42,859,142
Ensembl chr 6:42,852,683...42,859,927
|
|
G |
Ogfrl1 |
opioid growth factor receptor-like 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of OGFRL1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 9:29,634,178...29,647,903
Ensembl chr 9:29,634,179...29,647,903
|
|
G |
Olr1201 |
olfactory receptor 1201 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of OR8B8 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:40,383,997...40,384,929
Ensembl chr 8:40,383,918...40,384,966
|
|
G |
P4hb |
prolyl 4-hydroxylase subunit beta |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of P4HB mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:109,736,459...109,748,070
Ensembl chr10:109,736,458...109,747,987
|
|
G |
Paep |
progestagen associated endometrial protein |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PAEP mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:2,935,396...2,938,883
|
|
G |
Pax6 |
paired box 6 |
multiple interactions affects expression |
ISO |
bisphenol A affects the reaction [Bucladesine affects the expression of PAX6 mRNA]; bisphenol A affects the reaction [Bucladesine affects the expression of PAX6 protein]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of PAX6 mRNA]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of PAX6 protein]; Paraquat affects the reaction [Bucladesine affects the expression of PAX6 mRNA]; Paraquat affects the reaction [Bucladesine affects the expression of PAX6 protein] Bucladesine affects the expression of PAX6 mRNA; Bucladesine affects the expression of PAX6 protein |
CTD |
PMID:31400064 |
|
NCBI chr 3:95,700,241...95,728,682
Ensembl chr 3:95,707,386...95,728,624
|
|
G |
Pcdh18 |
protocadherin 18 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PCDH18 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:138,819,957...138,833,932
Ensembl chr 2:138,819,960...138,833,933
|
|
G |
Pcdhb5 |
protocadherin beta 5 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PCDHB4 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr18:30,398,113...30,400,695
Ensembl chr18:30,398,113...30,400,695
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions increases expression |
ISO EXP |
Metformin inhibits the reaction [Bucladesine results in increased expression of PCK1 mRNA] Lithium Chloride inhibits the reaction [Bucladesine results in increased expression of PCK1 mRNA] |
CTD |
PMID:1371108 PMID:24428821 |
|
NCBI chr 3:171,213,936...171,219,885
Ensembl chr 3:171,213,936...171,219,871
|
|
G |
Pdgfa |
platelet derived growth factor subunit A |
decreases expression |
ISO |
Bucladesine results in decreased expression of PDGFA mRNA |
CTD |
PMID:1650039 |
|
NCBI chr12:17,734,141...17,756,186
Ensembl chr12:17,734,133...17,755,285
|
|
G |
Pdk1 |
pyruvate dehydrogenase kinase 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PDK1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:58,530,870...58,561,494
Ensembl chr 3:58,530,870...58,558,027
|
|
G |
Pf4 |
platelet factor 4 |
increases expression multiple interactions |
ISO |
Bucladesine results in increased expression of PF4 mRNA [Bucladesine co-treated with Tetrachlorodibenzodioxin] results in increased expression of PF4 mRNA |
CTD |
PMID:21979172 |
|
NCBI chr14:18,848,549...18,849,258
Ensembl chr14:18,848,549...18,849,258
|
|
G |
Pgrmc2 |
progesterone receptor membrane component 2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PGRMC2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:127,986,106...128,002,005
Ensembl chr 2:127,986,109...128,002,005
|
|
G |
Pitpnc1 |
phosphatidylinositol transfer protein, cytoplasmic 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PITPNC1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:95,429,879...95,697,734
|
|
G |
Pkd2l1 |
polycystin 2 like 1, transient receptor potential cation channel |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PKD2L1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:263,922,201...263,959,318
Ensembl chr 1:263,922,201...263,959,318
|
|
G |
Plat |
plasminogen activator, tissue type |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PLAT mRNA |
CTD |
PMID:20823114 |
|
NCBI chr16:74,098,263...74,122,897
Ensembl chr16:74,098,260...74,122,889
|
|
G |
Plekhg3 |
pleckstrin homology and RhoGEF domain containing G3 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PLEKHG3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 6:99,612,993...99,655,753
Ensembl chr 6:99,625,306...99,655,362
|
|
G |
Plin1 |
perilipin 1 |
increases expression multiple interactions |
ISO |
Bucladesine results in increased expression of PLIN1 mRNA LIPE protein affects the reaction [Bucladesine results in increased expression of PLIN1 mRNA] |
CTD |
PMID:23362264 |
|
NCBI chr 1:141,458,907...141,470,927
Ensembl chr 1:141,458,181...141,471,010
|
|
G |
Pls3 |
plastin 3 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PLS3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr X:119,030,311...119,124,268
Ensembl chr X:119,030,419...119,124,250
|
|
G |
Pmp22 |
peripheral myelin protein 22 |
multiple interactions increases activity |
ISO |
Ascorbic Acid inhibits the reaction [Bucladesine results in increased activity of PMP22 promoter] |
CTD |
PMID:15034573 |
|
NCBI chr10:49,538,588...49,568,583
Ensembl chr10:49,538,588...49,568,583
|
|
G |
Pnpla6 |
patatin-like phospholipase domain containing 6 |
increases expression multiple interactions |
ISO |
Bucladesine results in increased expression of PNPLA6 mRNA Bucladesine results in increased expression of and results in increased activity of PNPLA6 protein; Cycloheximide inhibits the reaction [Bucladesine results in increased activity of PNPLA6 protein] |
CTD |
PMID:20380879 |
|
NCBI chr12:2,068,749...2,098,139
Ensembl chr12:2,069,959...2,097,904
|
|
G |
Pomc |
proopiomelanocortin |
increases expression |
ISO |
Bucladesine results in increased expression of POMC mRNA; Bucladesine results in increased expression of POMC protein modified form |
CTD |
PMID:1325994 |
|
NCBI chr 6:28,382,937...28,388,771
Ensembl chr 6:28,382,962...28,388,967
|
|
G |
Pou5f1 |
POU class 5 homeobox 1 |
affects expression multiple interactions |
ISO |
Bucladesine affects the expression of POU5F1 mRNA; Bucladesine affects the expression of POU5F1 protein bisphenol A affects the reaction [Bucladesine affects the expression of POU5F1 mRNA]; bisphenol A affects the reaction [Bucladesine affects the expression of POU5F1 protein]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of POU5F1 mRNA]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of POU5F1 protein]; Paraquat affects the reaction [Bucladesine affects the expression of POU5F1 mRNA]; Paraquat affects the reaction [Bucladesine affects the expression of POU5F1 protein] |
CTD |
PMID:31400064 |
|
NCBI chr20:3,747,231...3,751,994
Ensembl chr20:3,747,221...3,751,994
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression multiple interactions |
ISO |
Bucladesine results in increased expression of PPARG protein [ciglitazone co-treated with Bucladesine] affects the expression of PPARG mRNA; [ciglitazone co-treated with Bucladesine] results in increased expression of PPARG protein |
CTD |
PMID:19698295 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression multiple interactions |
ISO |
Bucladesine results in increased expression of PPARGC1A mRNA; Bucladesine results in increased expression of PPARGC1A protein IL22 protein inhibits the reaction [Bucladesine results in increased expression of PPARGC1A protein]; Metformin inhibits the reaction [Bucladesine results in increased expression of PPARGC1A mRNA] |
CTD |
PMID:24428821 PMID:26064446 |
|
NCBI chr14:63,095,291...63,190,688
Ensembl chr14:63,095,720...63,187,009
|
|
G |
Ppia |
peptidylprolyl isomerase A |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PPIA mRNA |
CTD |
PMID:20823114 |
|
NCBI chr14:86,673,775...86,677,443
Ensembl chr14:86,673,775...86,677,443
|
|
G |
Prima1 |
proline rich membrane anchor 1 |
increases expression |
EXP |
Bucladesine results in increased expression of PRIMA1 mRNA |
CTD |
PMID:18514641 |
|
NCBI chr 6:127,075,954...127,127,985
Ensembl chr 6:127,075,954...127,127,413
|
|
G |
Prkaca |
protein kinase cAMP-activated catalytic subunit alpha |
multiple interactions increases activity |
EXP |
KT 5720 inhibits the reaction [Bucladesine results in increased activity of PRKACA protein] |
CTD |
PMID:31300867 |
|
NCBI chr19:25,095,089...25,118,869
Ensembl chr19:25,095,089...25,118,860
|
|
G |
Prl |
prolactin |
multiple interactions |
ISO |
[Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of PRL mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of PRL protein; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL protein |
CTD |
PMID:20823114 PMID:30328349 |
|
NCBI chr17:39,814,236...39,824,299
Ensembl chr17:39,814,244...39,824,299
|
|
G |
Prss12 |
serine protease 12 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PRSS12 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:227,657,983...227,717,884
Ensembl chr 2:227,657,983...227,717,884
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [Dinoprostone results in increased expression of PTGS2 mRNA]]; Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [Dinoprostone results in increased expression of PTGS2 protein]]; Bucladesine promotes the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] Bucladesine promotes the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein] |
CTD |
PMID:11095985 PMID:12164941 PMID:24003391 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Ptk7 |
protein tyrosine kinase 7 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PTK7 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 9:16,662,588...16,729,888
Ensembl chr 9:16,702,460...16,729,030
|
|
G |
Ptpa |
protein phosphatase 2 phosphatase activator |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PTPA mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:8,982,122...9,012,585
Ensembl chr 3:8,982,122...9,012,585
|
|
G |
Rab1b |
RAB1B, member RAS oncogene family |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of RAB1B mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:220,483,529...220,491,469
Ensembl chr 1:220,480,834...220,491,469
|
|
G |
Rab31 |
RAB31, member RAS oncogene family |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of RAB31 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 9:113,370,072...113,504,606
Ensembl chr 9:113,370,033...113,504,605
|
|
G |
Ran |
RAN, member RAS oncogene family |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of RAN mRNA |
CTD |
PMID:20823114 |
|
NCBI chr12:31,319,556...31,324,105
Ensembl chr12:31,320,624...31,323,810
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
decreases activity decreases phosphorylation multiple interactions |
ISO EXP |
Bucladesine results in decreased activity of RB1 protein Bucladesine results in decreased phosphorylation of RB1 protein Bucladesine inhibits the reaction [CASP3 protein results in increased cleavage of RB1 protein] |
CTD |
PMID:10697531 PMID:16718685 |
|
NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
|
|
G |
Ren |
renin |
increases secretion increases expression |
ISO |
Bucladesine results in increased secretion of REN protein Bucladesine results in increased expression of REN mRNA |
CTD |
PMID:9256163 |
|
NCBI chr13:50,502,724...50,513,953
Ensembl chr13:50,502,724...50,514,151
|
|
G |
Ret |
ret proto-oncogene |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of RET mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:150,202,170...150,249,196
Ensembl chr 4:150,202,058...150,244,372
|
|
G |
Rgs10 |
regulator of G-protein signaling 10 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of RGS10 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:199,782,076...199,823,440
Ensembl chr 1:199,782,078...199,823,386
|
|
G |
Rhobtb3 |
Rho-related BTB domain containing 3 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of RHOBTB3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:2,627,655...2,683,305
Ensembl chr 2:2,627,393...2,683,116
|
|
G |
Rin1 |
Ras and Rab interactor 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of RIN1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:220,335,036...220,342,319
Ensembl chr 1:220,335,254...220,342,297 Ensembl chr 1:220,335,254...220,342,297
|
|
G |
Rpn1 |
ribophorin I |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of RPN1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:119,997,232...120,018,687
Ensembl chr 4:119,997,268...120,018,679
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of RPS6KB1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:73,824,200...73,865,503
Ensembl chr10:73,824,202...73,865,364
|
|
G |
Rpsa |
ribosomal protein SA |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of RPSA mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:128,806,053...128,809,987
Ensembl chr 8:128,806,129...128,809,986
|
|
G |
S100a14 |
S100 calcium binding protein A14 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of S100A14 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:189,913,433...189,919,947
|
|
G |
Saraf |
store-operated calcium entry-associated regulatory factor |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of SARAF mRNA |
CTD |
PMID:20823114 |
|
NCBI chr16:61,735,189...61,753,438
Ensembl chr16:61,735,181...61,753,476
|
|
G |
Scamp4 |
secretory carrier membrane protein 4 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of SCAMP4 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 7:11,969,720...11,982,141
Ensembl chr 7:11,969,720...11,982,141
|
|
G |
Scarb1 |
scavenger receptor class B, member 1 |
multiple interactions increases expression |
ISO EXP |
LIPE protein affects the reaction [Bucladesine results in increased expression of SCARB1 mRNA] |
CTD |
PMID:23045399 PMID:23362264 |
|
NCBI chr12:36,694,952...36,761,445
Ensembl chr12:36,694,960...36,761,455
|
|
G |
Sdcbp |
syndecan binding protein |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of SDCBP mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:19,471,664...19,498,499
Ensembl chr 5:19,471,664...19,498,485
|
|
G |
Selenot |
selenoprotein T |
multiple interactions increases expression |
EXP |
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Bucladesine results in increased expression of SELENOT mRNA]; nickel chloride inhibits the reaction [Bucladesine results in increased expression of SELENOT mRNA] |
CTD |
PMID:18198219 |
|
NCBI chr 2:148,765,412...148,781,080
Ensembl chr 2:148,765,412...148,780,276
|
|
G |
Sema3a |
semaphorin 3A |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of SEMA3A mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:18,170,375...18,545,190
Ensembl chr 4:18,178,656...18,396,035
|
|
G |
Septin11 |
septin 11 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of SEPTIN11 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr14:16,369,544...16,405,645
Ensembl chr14:16,369,544...16,452,998
|
|
G |
Sfn |
stratifin |
multiple interactions |
ISO |
[Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in increased expression of SFN mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of SFN protein |
CTD |
PMID:22534328 |
|
NCBI chr 5:151,823,422...151,824,937
Ensembl chr 5:151,823,887...151,824,633
|
|
G |
Slc18a3 |
solute carrier family 18 member A3 |
increases expression multiple interactions |
EXP |
Bucladesine results in increased expression of SLC18A3 protein Nicotine promotes the reaction [Bucladesine results in increased expression of SLC18A3 protein] |
CTD |
PMID:20361958 |
|
NCBI chr16:8,682,668...8,685,529
Ensembl chr16:8,682,669...8,685,529
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
multiple interactions |
ISO |
[Progesterone co-treated with Bucladesine] results in increased expression of SLC2A1 protein |
CTD |
PMID:18948400 |
|
NCBI chr 5:138,154,677...138,182,897
Ensembl chr 5:138,154,673...138,182,897
|
|
G |
Slc2a5 |
solute carrier family 2 member 5 |
multiple interactions |
ISO |
Bucladesine results in increased expression of and results in increased stability of SLC2A5 mRNA; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of and results in increased stability of SLC2A5 mRNA] |
CTD |
PMID:12820898 |
|
NCBI chr 5:167,142,182...167,174,203
Ensembl chr 5:167,141,875...167,174,310
|
|
G |
Smad6 |
SMAD family member 6 |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [BMP4 protein results in increased expression of SMAD6 mRNA] |
CTD |
PMID:20522807 |
|
NCBI chr 8:68,897,746...68,967,221
Ensembl chr 8:68,898,296...68,966,108
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions increases expression increases activity |
ISO |
Bucladesine promotes the reaction [CREBBP protein binds to SOD2 promoter]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of SOD2 mRNA]; protein kinase inhibitor peptide inhibits the reaction [Bucladesine results in increased activity of SOD2 protein] |
CTD |
PMID:12093828 PMID:20685861 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
G |
Sox1 |
SRY-box transcription factor 1 |
multiple interactions affects expression |
ISO |
bisphenol A affects the reaction [Bucladesine affects the expression of SOX1 mRNA]; bisphenol A affects the reaction [Bucladesine affects the expression of SOX1 protein]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of SOX1 mRNA]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of SOX1 protein]; Paraquat affects the reaction [Bucladesine affects the expression of SOX1 mRNA]; Paraquat affects the reaction [Bucladesine affects the expression of SOX1 protein] Bucladesine affects the expression of SOX1 mRNA; Bucladesine affects the expression of SOX1 protein |
CTD |
PMID:31400064 |
|
|
|
G |
Srsf7 |
serine and arginine rich splicing factor 7 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of SRSF7 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 6:2,879,312...2,886,505
Ensembl chr 6:2,880,518...2,886,465
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions increases expression decreases expression |
ISO EXP |
27-hydroxycholesterol promotes the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; [[TO-901317 co-treated with LG 100268] promotes the reaction [Bucladesine results in increased phosphorylation of STAR protein]] which results in increased abundance of Progesterone; [Bucladesine co-treated with ciglitazone] results in increased expression of STAR mRNA; [Bucladesine co-treated with ciglitazone] results in increased phosphorylation of STAR protein; [Bucladesine co-treated with LIPE protein] results in increased expression of and results in increased phosphorylation of STAR protein; [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]] promotes the reaction [CREBBP protein binds to STAR promoter]; [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein] which results in increased abundance of Progesterone; [Bucladesine results in increased expression of STAR protein] which results in increased abundance of Progesterone; [ciglitazone co-treated with Bucladesine] promotes the reaction [JUN protein results in increased expression of STAR mRNA]; [TO-901317 co-treated with LG 100268] promotes the reaction [Bucladesine results in increased phosphorylation of STAR protein]; alpha-hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; alpha-hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR protein]; bisindolylmaleimide I inhibits the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; bisindolylmaleimide I inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; bisindolylmaleimide I inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR protein]]; Bucladesine promotes the reaction [ciglitazone results in increased expression of STAR mRNA]; Bucladesine promotes the reaction [ciglitazone results in increased expression of STAR protein]; Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]; Bucladesine promotes the reaction [LG 100268 promotes the reaction [[TO-901317 results in increased expression of STAR mRNA] which results in increased abundance of Progesterone]]; Bucladesine promotes the reaction [LG 100268 promotes the reaction [[TO-901317 results in increased expression of STAR protein] which results in increased abundance of Progesterone]]; Bucladesine promotes the reaction [LG 100268 promotes the reaction [TO-901317 results in increased expression of STAR mRNA]]; Bucladesine promotes the reaction [TO-901317 promotes the reaction [[LG 100268 results in increased expression of STAR mRNA] which results in increased abundance of Progesterone]]; Bucladesine promotes the reaction [TO-901317 promotes the reaction [[LG 100268 results in increased expression of STAR protein] which results in increased abundance of Progesterone]]; Bucladesine promotes the reaction [TO-901317 promotes the reaction [LG 100268 results in increased expression of STAR mRNA]]; Bucladesine results in increased expression of and results in increased phosphorylation of STAR mRNA; Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein; CAY 10499 inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]; ciglitazone promotes the reaction [Bucladesine results in increased expression of STAR mRNA]; ciglitazone promotes the reaction [Bucladesine results in increased expression of STAR protein]; CREB1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; CREBBP protein promotes the reaction [CREB1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]]; delta-hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; delta-hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR protein]; GFX 109203x inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; Hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; Hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR protein]; lead acetate inhibits the reaction [Bucladesine results in increased expression of STAR protein]; LIPE protein affects the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]; LIPE protein affects the reaction [Bucladesine results in increased expression of STAR mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; NR0B1 protein inhibits the reaction [[Bucladesine results in increased expression of STAR protein] which results in increased abundance of Progesterone]; NR0B1 protein inhibits the reaction [NR4A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR0B1 protein inhibits the reaction [NR5A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR1H2 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; NR1H3 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; NR4A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]; NR4A1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR5A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]; Probucol inhibits the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 mRNA]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; Tetradecanoylphorbol Acetate promotes the reaction [[Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein] which results in increased abundance of Progesterone]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR mRNA]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR protein]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased phosphorylation of STAR protein]; U 0126 inhibits the reaction [Bucladesine results in increased phosphorylation of STAR protein]; U 0126 inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased phosphorylation of STAR protein]] Bucladesine results in increased expression of STAR mRNA; Bucladesine results in increased expression of STAR protein Bucladesine results in decreased expression of STAR mRNA [Atrazine co-treated with Bucladesine] results in increased expression of STAR mRNA; Atrazine inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of STAR mRNA] |
CTD |
PMID:10964798 PMID:10993823 PMID:11213355 PMID:18755854 PMID:18787026 PMID:19253104 PMID:19282384 PMID:19698295 PMID:20083572 PMID:21047949 PMID:21693180 PMID:21979172 PMID:23200735 PMID:23362264 |
|
NCBI chr16:71,036,204...71,040,847
Ensembl chr16:71,036,204...71,040,847
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
STAT3 gene mutant form affects the reaction [IL22 protein inhibits the reaction [Bucladesine results in increased expression of G6PC protein]] |
CTD |
PMID:26064446 |
|
NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
|
|
G |
Stk38 |
serine/threonine kinase 38 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of STK38 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr20:6,224,300...6,257,613
Ensembl chr20:6,224,296...6,257,604
|
|
G |
Sulf1 |
sulfatase 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of SULF1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:5,999,520...6,186,901
Ensembl chr 5:5,999,475...6,186,329
|
|
G |
Tagln |
transgelin |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of TAGLN mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:50,222,895...50,228,369
Ensembl chr 8:50,222,896...50,231,357
|
|
G |
Tcea1 |
transcription elongation factor A1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of TCEA1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:14,511,183...14,548,494
Ensembl chr 5:14,511,183...14,548,429
|
|
G |
Tert |
telomerase reverse transcriptase |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of TERT mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:32,250,876...32,275,330
Ensembl chr 1:32,251,714...32,272,476
|
|
G |
Testin |
testin gene |
decreases expression multiple interactions |
EXP |
Bucladesine results in decreased expression of TESTIN mRNA Dactinomycin inhibits the reaction [Bucladesine results in decreased expression of TESTIN mRNA]; lonidamine inhibits the reaction [Bucladesine results in decreased expression of TESTIN mRNA] |
CTD |
PMID:11090432 |
|
NCBI chr17:4,194,796...4,225,376
Ensembl chr17:4,212,890...4,225,376
|
|
G |
Tfrc |
transferrin receptor |
decreases expression |
ISO |
Bucladesine results in decreased expression of TFRC protein |
CTD |
PMID:2989362 |
|
NCBI chr11:71,397,423...71,419,263
Ensembl chr11:71,397,383...71,419,223
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]; Bucladesine inhibits the reaction [TGFB1 protein results in increased expression of COL3A1 mRNA] |
CTD |
PMID:11576339 PMID:16430859 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Tgm2 |
transglutaminase 2 |
multiple interactions |
ISO |
[O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate co-treated with Bucladesine] results in increased activity of TGM2 protein; [phenylsaligenin cyclic phosphate co-treated with Bucladesine] results in increased activity of TGM2 protein |
CTD |
PMID:32749514 |
|
NCBI chr 3:154,597,165...154,627,257
Ensembl chr 3:154,597,168...154,627,257
|
|
G |
Th |
tyrosine hydroxylase |
increases expression |
EXP |
Bucladesine results in increased expression of TH mRNA |
CTD |
PMID:19912776 |
|
NCBI chr 1:216,073,034...216,080,287
Ensembl chr 1:216,073,031...216,080,287
|
|
G |
Tjp1 |
tight junction protein 1 |
multiple interactions |
EXP |
Bucladesine inhibits the reaction [tert-Butylhydroperoxide affects the localization of TJP1 protein] |
CTD |
PMID:16716901 |
|
NCBI chr 1:126,146,489...126,515,359
Ensembl chr 1:126,146,489...126,227,469
|
|
G |
Tnc |
tenascin C |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of TNC mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:79,789,686...79,874,555
Ensembl chr 5:79,789,671...79,874,671
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Bucladesine inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] Bucladesine inhibits the reaction [Dopamine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]]; Bucladesine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein] Bucladesine inhibits the reaction [Zymosan results in increased expression of TNF protein] |
CTD |
PMID:11301049 PMID:12509806 PMID:12538815 PMID:15081246 PMID:20388727 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000 Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
[Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in increased expression of TP53 protein; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of TP53 protein |
CTD |
PMID:22534328 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Tpi1 |
triosephosphate isomerase 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of TPI1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:157,328,375...157,331,905
Ensembl chr 4:157,328,379...157,331,905 Ensembl chr 9:157,328,379...157,331,905
|
|
G |
Tpsg1 |
tryptase gamma 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of TPSG1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:14,724,531...14,731,259
Ensembl chr10:14,727,180...14,731,086
|
|
G |
Txn1 |
thioredoxin 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of TXN mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:75,049,735...75,057,731
Ensembl chr 5:75,049,747...75,057,752
|
|
G |
Ube2d4 |
ubiquitin-conjugating enzyme E2D 4 (putative) |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of UBE2D4 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr14:2,933,097...2,934,571
Ensembl chr14:2,933,100...2,934,571
|
|
G |
Ucp1 |
uncoupling protein 1 |
increases expression multiple interactions |
EXP |
Bucladesine results in increased expression of UCP1 mRNA N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of UCP1 mRNA] |
CTD |
PMID:12414803 |
|
NCBI chr19:24,456,976...24,464,808
Ensembl chr19:24,456,976...24,464,807
|
|
G |
Ugcg |
UDP-glucose ceramide glucosyltransferase |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of UGCG mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:76,376,722...76,419,564
Ensembl chr 5:76,386,836...76,419,560
|
|
G |
Usp12 |
ubiquitin specific peptidase 12 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of USP12 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr12:10,037,686...10,087,685
Ensembl chr12:10,063,117...10,087,685
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression |
ISO |
Bucladesine results in increased expression of VEGFA mRNA |
CTD |
PMID:18591213 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
G |
Vim |
vimentin |
multiple interactions |
ISO |
[Azacitidine co-treated with Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of VIM protein |
CTD |
PMID:20823114 |
|
NCBI chr17:80,882,715...80,891,200
Ensembl chr17:80,882,666...80,891,212
|
|
G |
Vps39 |
VPS39 subunit of HOPS complex |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of VPS39 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:112,087,213...112,125,307
Ensembl chr 3:112,087,677...112,125,318
|
|
G |
Wnt5a |
Wnt family member 5A |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of WNT5A mRNA |
CTD |
PMID:20823114 |
|
NCBI chr16:4,469,451...4,490,271
Ensembl chr16:4,469,468...4,489,860
|
|
G |
Wwtr1 |
WW domain containing transcription regulator 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of WWTR1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:147,577,149...147,693,033
Ensembl chr 2:147,577,089...147,693,082
|
|
G |
Zbtb45 |
zinc finger and BTB domain containing 45 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of ZBTB45 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:65,563,999...65,568,301
Ensembl chr 1:65,564,173...65,568,300
|
|
G |
Zscan10 |
zinc finger and SCAN domain containing 10 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of ZSCAN10 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:12,929,471...12,939,439
Ensembl chr10:12,929,471...12,939,435
|
|
G |
Zscan20 |
zinc finger and SCAN domain containing 20 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of ZSCAN20 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:146,760,822...146,788,945
Ensembl chr 5:146,762,683...146,787,676
|
|